MA
PRTK

Montag & Associates’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Montag & Associates’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-100
Closed – – 865
2022
Q1 		$0 Hold
100
– – ﹤0.01% 893
2021
Q4 		$0 Hold
100
– – ﹤0.01% 926
2021
Q3 		$0 Hold
100
– – ﹤0.01% 901
2021
Q2 		$1K Hold
100
– – ﹤0.01% 856
2021
Q1 		$1K Hold
100
– – ﹤0.01% 857
2020
Q4 		$1K Buy
+100
New +$588 ﹤0.01% 784

Other funds holding PRTK

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FIG
Fortress Investment Group New York $394M AUM 22.99% 1-Year Est. Return

Montag & Associates's PRTK Position: Q2 2022 in Review

Montag & Associates sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2022, closing a stake of 100 shares.

Montag & Associates first reported a position in PRTK in Q4 2020 and held it in 6 quarters. The position peaked at $1K in Q2 2021. 84 funds tracked by Wall St. Rank hold PRTK as of Q2 2022.

  • Montag & Associates reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
  • Montag & Associates sold 100 Paratek Pharmaceuticals, Inc. shares in Q2 2022.
  • Montag & Associates first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2020 and held it in 6 quarters.
  • Montag & Associates's Paratek Pharmaceuticals, Inc. position peaked at $1K in Q2 2021.
  • 84 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2022.

Based on Montag & Associates's 13F filing for Q2 2022, filed 10 Aug 2022.